Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (131-140 of 208) with videos related to

Pageof 21
Sort By:
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Cancer Research|March 3, 2004
Genetics and cytogenetics of multiple myeloma: a workshop reportRafael Fonseca, Bart Barlogie, Regis Bataille, et al.
Mayo Clinic Proceedings|April 23, 2021
Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice SettingJennifer L Anderson, Teresa M Kruisselbrink, Emily C Lisi, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Annals of Hematology|April 7, 2018
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patientsVerónica González-Calle, Abigail Slack, Niamh Keane, et al.
The Lancet. Oncology|December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
Multidisciplinary model to implement pharmacogenomics at the point of carePedro J Caraballo, Lucy S Hodge, Suzette J Bielinski, et al.
Plos One|February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangementsJan B Egan, Michael T Barrett, Mia D Champion, et al.
Pageof 21

Showing results (131-140 of 208) with videos related to

Sort By:
Pageof 21
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Cancer Research|March 3, 2004
Genetics and cytogenetics of multiple myeloma: a workshop reportRafael Fonseca, Bart Barlogie, Regis Bataille, et al.
Mayo Clinic Proceedings|April 23, 2021
Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice SettingJennifer L Anderson, Teresa M Kruisselbrink, Emily C Lisi, et al.
Blood|July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesK Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Annals of Hematology|April 7, 2018
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patientsVerónica González-Calle, Abigail Slack, Niamh Keane, et al.
The Lancet. Oncology|December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
Multidisciplinary model to implement pharmacogenomics at the point of carePedro J Caraballo, Lucy S Hodge, Suzette J Bielinski, et al.
Plos One|February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangementsJan B Egan, Michael T Barrett, Mia D Champion, et al.
Pageof 21